Videos

John Tesser, MD; Nehad Soloman, MD; and Jennifer Simpson, DNP, profile classes of interleukin inhibitors and the potential benefits for patients with psoriatic arthritis.

Before closing out their discussion on psoriatic arthritis management, two experts consider how the COVID-19 pandemic has affected their practice.

Daniel J. Lovell, MD, MPH, explains the recent ACR guidelines updates regarding the treatment and management of juvenile idiopathic arthritis and the clinical significance of the changes.

Resources that can help educate patients with lupus about their diagnosis and encourage them to take a more proactive role in self-care.

Types of tests used to evaluate patients for signs of lupus or disease progression.

Roy Fleischmann, MD, discusses the usage of biosimilars in the United States and hypothesizes about what is in store for the future.

Roy Fleischmann, MD, examines the current state of biosimilars as it relates to rheumatologists in the United States.

Roy Fleischmann, MD, explains the history of biosimilars in rheumatology as well as implementing biosimilars in the United States.

The panel explains the many conventional DMARDs that can be used to treat psoriatic arthritis, as well as their role in management.

John Tesser, MD; Nehad Soloman, MD; and Jennifer Simpson, DNP, talk about the importance of shared decision-making in the treatment of psoriatic arthritis.

Thought leaders discuss differences in recommendations between guidelines for the management of psoriatic arthritis.

John Tesser, MD; Nehad Soloman, MD; and Jennifer Simpson, DNP, discuss the common triggers patients with psoriatic arthritis and the importance of stress management.

Shared insight on technical processes and protocols used to manage patients with psoriatic arthritis, including those for prescription fulfillment.

A brief overview on the drivers of noncompliance and treatment adherence in patients with psoriatic arthritis.

Types of patient populations at higher risk for developing more severe forms of lupus.

Criteria used by rheumatologists to help classify lupus due to its heterogenous manifestation.

Rheumatology Network interviewed Jeffrey Stark, MD, to discuss the BE COMPLETE study, which examined the efficacy of bimekizumab for treating psoriatic arthritis.

Expert John Sergent, MD, goes into detail about myositis and how to differentiate it from other inflammatory diseases.

These prominent leaders in the field of autoimmune disease discuss AHN's Autoimmunity Institute joining forces with the Relapsing Polychondritis Foundation.

Expert perspectives on the importance of establishing good patient-provider relationships while managing psoriatic arthritis.

Reflections on the challenges inherent in managing psoriatic arthritis, particularly cost of care and educating patients on their disease.

Why is Rare Disease Day so important? Hear the answers from some of the most qualified professionals in rare disease fields.

Uma Mahadevan, MD, gives Rheumatology Network an overview of her Rheumatology Winter Clinical Symposium presentation, “Gastroenterology Update for the Rheumatologist.”

Anisha Dua, MD, MPH, discusses the mimics, related conditions, and new diseases in the field of vasculitis as it relates to rheumatology.

Vibeke Strand, MD, shares that based on her data, secukinumab is an effective option for treating patients with psoriatic arthritis.

Experts delve into considerations regarding management of comorbidities in patients with psoriatic arthritis.

John Tesser, MD; Nehad Soloman, MD; and Jennifer Simpson, DNP, talk about the importance of patient communication and the role of advanced practice clinicians.

Roy Fleishmann, MD, discusses his Rheumatology Winter Clinical Symposium presentation, “Beyond the package insert: JAK inhibitors (jakinibs): safety issues.”

The Chair of the ACR COVID-19 Vaccine Clinical Guidance Task Force shares what was learned from the Omicron variant and how the recommendations for rheumatologists has been affected by it.

Experts consider optimal treatment strategies for patients with treatment-resistant psoriatic arthritis.